Enliven Therapeutics

ELVNPhase 1

Enliven Therapeutics is a clinical-stage biotech company advancing a pipeline of small molecule kinase inhibitors designed to overcome key limitations of existing cancer therapies. The company leverages a team of seasoned drug hunters with proven track records in discovering and commercializing oncology drugs, including multiple FDA-approved therapies. Enliven's strategy focuses on developing highly selective inhibitors that address resistance mechanisms, improve safety, and penetrate the central nervous system to treat brain metastases. With a lead program in CML showing promising early data and a clear clinical development roadmap for 2026, the company is positioned to advance multiple precision oncology candidates.

Market Cap

$1.7B

Focus

Small Molecules

ELVN · Stock Price

USD 29.03+21.27 (+274.10%)

Historical price data

AI Company Overview

Technology Platform

A platform for designing next-generation small molecule kinase inhibitors with enhanced selectivity, combinability, mechanisms to combat resistance, CNS penetration for brain metastases, and improved safety profiles.

Pipeline Snapshot

4 drugs in pipeline

Drug	Indication	Stage
ELVN-001	Chronic Myeloid Leukemia	Phase 1
ELVN-002 + Fam-Trastuzumab Deruxtecan-Nxki + Trastuzumab emtansine	HER2 Mutant Non-small Cell Lung Cancer	Phase 1
ELVN-002 + Trastuzumab + 5-Fluorouracil + Oxaliplatin + Capecitabine + Eribulin ...	HER2-positive Breast Cancer	Phase 1
ELVN-001	CML (Chronic Myelogenous Leukemia)	Phase 1

Funding History

Total raised: $338M

IPO$168MUndisclosedJun 30, 2023

Series B$115MRA Capital ManagementDec 15, 2020

Series A$55MForesite CapitalMay 15, 2019

Opportunities

Significant opportunity exists in advancing ELVN-001 in CML, particularly for patients resistant or intolerant to existing therapies.

The company's platform can be leveraged to develop inhibitors for other kinase targets in oncology with high unmet need, especially in cancers prone to brain metastases.

Strategic partnerships for co-development or ex-US commercialization could provide non-dilutive funding and accelerate pipeline expansion.

Risk Factors

Key risks include clinical failure of ELVN-001 in later-stage trials, intense competition from established and novel CML therapies, potential difficulty in demonstrating sufficient differentiation for regulatory approval and market adoption, and dependence on capital markets for funding as a pre-revenue company.

Competitive Landscape

Enliven faces direct competition in CML from multiple approved BCR-ABL inhibitors (e.g., imatinib, dasatinib, nilotinib, ponatinib, asciminib). Its broader platform competes with numerous biopharma companies developing kinase inhibitors. Differentiation hinges on ELVN-001's clinical profile regarding safety, efficacy in resistant disease, and CNS activity, as well as the team's ability to efficiently discover and develop next-generation inhibitors.

Publications

Patents

Pipeline